Short-term effect of low-dose roxadustat combined with erythropoiesis-stimulating agent treatment for erythropoietin-resistant anemia in patients undergoing maintenance hemodialysis
BackgroundErythropoietin resistance is present in some patients with chronic kidney disease, especially in those undergoing hemodialysis, and is often treated using roxadustat rather than iron supplements and erythropoiesis-stimulating agents (ESAs). However, some patients cannot afford full doses o...
Sparad:
| Huvudupphov: | , , , , , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Utgiven: |
Frontiers Media S.A.
2024-07-01
|
| Serie: | Frontiers in Endocrinology |
| Ämnen: | |
| Länkar: | https://www.frontiersin.org/articles/10.3389/fendo.2024.1372150/full |
| Taggar: |
Inga taggar, Lägg till första taggen!
|